Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial

Summary

In a randomized triple-blind multicentre study, injections with the anti-androgenic agent oxendolone were compared with placebo in the treatment of benign prostatic hyperplasia. Thirty patients were treated with weekly injections of oxendolone 200 mg during a 3 months' period, and 30 patients were allocated to placebo treatment. During oxendolone treatment the maximum urinary flow rate increased statistically significantly (from 6.8 ml/s to 8.2 ml/s). However compared to placebo, the oxendolone effect was statistically insignificant. A slight but statistically significant improvement of the symptoms ‘sensation of retention”, “urgency” and “frequency”, was observed following oxendolone treatment, but an almost identical effect was seen in the placebo group. Following either treatment no change was observed in the residual urine volumes, in prostatic volume as measured by transrectal ultrasonotomography, or in any other therapeutic parameters. Conservative treatment of benign prostatic hyperplasia with the antiandrogen oxendolone in a dose of 200 mg a week cannot be recommended for clinical use.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Abrams PH (1977) A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy. Br J Urol 49:67–71

  2. 2.

    Clark R (1937) The prostate and endocrine therapy, a control series. Br J Urol 9:254–271

  3. 3.

    Drach W, Layton T, Bottaccini R (1982) A method of adjustment of male peak urinary flow rate for varying age and volume voided. J Urol 128:960–962

  4. 4.

    Jensen SK, Hammen S (1980) Treatment of benign hypertrophy of the prostate with candicidin. Ugeskr Læger 144:26–27

  5. 5.

    Katsumi T, Kawaguchi K, Murayama K, Hisazumi H (1982) Studies on long-term efficacy and safety of TSAA-291 in benign prostatic hypertrophy: With particular emphasis on its effect on blood hormones. Acta Urol Jpn 28:1193–1200

  6. 6.

    Madsen PO, Dørflinger T, Frimodt-Møller PC, Jensen M-E (1984) Candicidine in treatment of benign prostatic hypertrophy. J Urol 132:1235–1238

  7. 7.

    Meyhoff HH, Ingemann L, Nordling J, Hald T (1981) Accuracy in preoperative estimation of the prostatic size. Scand J Urol Nefrol 15:45–51

  8. 8.

    Saitoh M, Watanabe H, Ohe H, Tanaka S, Itakura Y (1979) The effect of TASAA-291 on patients with benign prostatic hypertrophy. Acta Urol Jpn 25:627–631

  9. 9.

    Scott WW, Wade JC (1969) Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetat. J Urol 101:81–85

  10. 10.

    Shimazaki J, Ohki Y, Koya A, Shida K (1972) Inhibition of nuclear Testosterone 5alfa-reductase in rat ventral prostate by estrogens and anti-androgenes. Endocrinol Jpn 19:585–588

  11. 11.

    Shida K, Yoshida O, Okada K, Kondo A, Nakano S, Shimazaki J, Kuroda K, Niijima T, Nihira H, Seto T (1980) Clinical study of antiandrogen (TSAA-291) on human benign prostatic hypertrophy-comparative study of administration of 200 mg/week, 400 mg/week and 600 mg/week. Acta Urol Jpn 26:353–367

  12. 12.

    Sudo K, Yoshida K, Kimura Y, Nakayama R (1979) Effects of the anti-androgen TSAA-291 on the androgen-receptor complex formation from H-3 testosterone in rat ventral prostates. Acta Endocrinol 92 [Suppl 229]:67–81

  13. 13.

    Sudo K, Yoshida K, Nakayama R (1979) Effects of the antiandrogen TSAA-291 and its related compounds on the in vitro formation of 5alpha-DHT-receptor complex in the cytosol of the rat ventral prostates. Acta Endocrinol 92 [Suppl 229]:82–99

  14. 14.

    Siiteri KP, Wilson JD (1970) The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49:1737–1745

  15. 15.

    Yoshida O, Okada K, Shida K, Kondo A, Saito Y, Tsuji I (1979) Clinical evaluation of TSAA-291 in treatment of benign prostatic hyperplasia by double blind study. Acta Urol Jpn 25:1077–1108

  16. 16.

    Wilson JD (1980) The pathogenesis of benign prostatic hyperplasia. Am J Med 80:745–756

  17. 17.

    Wolf H, Madsen PO (1968) Treatment of benign prostatic hypertrophy with progestional agents: a preliminary report. J Urol 99:780–785

Download references

Author information

Additional information

{ogClinical Affairs}{onH. Lundbeck A/S}{cyDenmark}

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ostri, P., Swartz, R., Meyhoff, H.-. et al. Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial. Urol. Res. 17, 29–33 (1989). https://doi.org/10.1007/BF00261046

Download citation

Key words

  • Benign prostatic hyperplasia
  • Prostatic hypertrophy
  • Medical treatment